Patents Assigned to Centers For Disease Control and Prevention

gparkof1 Covid 19, In the News

Patents Assigned to Centers For Disease Control and Prevention
  • Recombinant Antigen Derived From Zika Virus E Protein And Use Thereof
    Publication number: 20200230227
    Abstract: The present invention relates to a recombinant antigen derived from Zika virus E protein and use thereof. Specifically, the present invention provides a polynucleotide encoding Zika virus E protein domain III alone or repeatedly three times, a recombinant plasmid vector comprising the polynucleotide, and a DNA vaccine composition that may induce an immune response to Zika virus by expressing a Zika virus antigen protein effectively. In addition, the present invention provides a neutralizing antibody against Zika virus obtained using the polynucleotide and a method for preparing the neutralizing antibody.
    Type: Application
    Filed: December 10, 2019
    Publication date: July 23, 2020
    Applicant: Korea Center For Disease Control And Prevention
    Inventors: You-Jin Kim, Hyun Ju In, HeeJi Lim, Sun-Dong Jang, Jung-Sik Yoo, Gyung Tae Chung
  • Modulation of replicative fitness by deoptimization of synonymous codons
    Patent number: 10695414
    Abstract: Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic compositions are also disclosed.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: June 30, 2020
    Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, Center for Disease Control and Prevention
    Inventors: Olen M. Kew, Cara Carthel Burns, Jing Shaw, Raymond Campagnoli, Jacqueline Quay
  • Anti-HIV vaccine constructed based on amino acid mutations in attenuated live EIAV vaccine
    Patent number: 10251948
    Abstract: Provided are antigenic polypeptides of HIV envelope glycoproteins which are constructed based on amino acid mutation of attenuated live vaccine of Equine Infectious Anemia Virus, DNA constructions and recombinant virus vectors comprising polynucleotides encoding said polypeptides, antibodies against said polypeptides as well as uses thereof in preventing and treating HIV infection. Said antigenic polypeptides and vaccines can induce high titer neutralization antibodies against HIV in organism.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: April 9, 2019
    Assignee: National Center for AIDS/STD Control And Prevention, Chinese Center for Disease Control and Prevention
    Inventors: Yiming Shao, Lianxing Liu, Rongxian Shen
  • Recombinant rift valley fever (RVF) viruses and methods of use
    Patent number: 10064933
    Abstract: Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: September 4, 2018
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Brian H. Bird, Cesar G. Albarino, Stuart T. Nichol, Thomas G. Ksiazek
  • Primers and probes for detection and discrimination of types and subtypes of influenza viruses
    Patent number: 10036076
    Abstract: Methods of detecting influenza, including differentiating between type and subtype are disclosed, for example to detect, type, and/or subtype an influenza infection. A sample suspected of containing a nucleic acid of an influenza virus, is screened for the presence or absence of that nucleic acid. The presence of the influenza virus nucleic acid indicates the presence of influenza virus. Determining whether the influenza virus nucleic acid is present in the sample can be accomplished by detecting hybridization between an influenza specific probe, influenza type specific probe, and/or subtype specific probe and an influenza nucleic acid. Probes and primers for the detection, typing and/or subtyping of influenza virus are also disclosed. Kits and arrays that contain the disclosed probes and/or primers also are disclosed.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: July 31, 2018
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Center for Disease Control and Prevention
    Inventors: Stephen Lindstrom, Lamorris Loftin
  • Materials and methods for respiratory disease control in canines
    Patent number: 9913892
    Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: March 13, 2018
    Assignees: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., CORNELL RESEARCH FOUNDATION, INC., THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION
    Inventors: Patti Cynthia Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, Nancy J. Cox, William L. Castleman
  • Attenuated vaccinia virus KVAC103 strain
    Patent number: 9879232
    Abstract: The attenuated vaccinia virus strain KVAC103 was obtained by subculturing a vaccinia virus strain 103 times in VERO cells. The attenuated vaccinia virus strain KVAC103 has significantly low toxicity, shows reduced skin lesions, and, at the same time, induces effectively immune responses to poxvirus. Thus, it can be used as a poxvirus vaccine while causing less side effects.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: January 30, 2018
    Assignee: KOREA CENTERS FOR DISEASE CONTROL AND PREVENTION
    Inventors: Sang Gu Yeo, Ho Sun Son, June Woo Lee, Seung Bin Cha, Sun Hwa Lee, Kwi Sung Park, Sang Won Lee
  • Recombinant vaccinia virus derived from KVAC103 strain
    Patent number: 9879281
    Abstract: Disclosed herein is a novel recombinant virus vector derived from the attenuated vaccinia virus strain KVAC103. The recombinant virus vector is obtained by inserting an exogenous gene into the KVAC103 and may be used as a safe vaccine delivery vehicle in mammals. Particularly, recombinant viruses obtained by rescuing some of the genes deleted from the parent virus have an enhanced ability to proliferate in cells being cultured, and thus are easily produced. In addition, the recombinant viruses express an increased level of an exogenous antigen, and thus has enhanced immunogenic efficacy. Such recombinant virus vectors may be used in vaccines for preventing diseases, therapeutic vaccines, and molecular biological studies.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: January 30, 2018
    Assignee: KOREA CENTERS FOR DISEASE CONTROL AND PREVENTION
    Inventors: Ho Sun Son, Sang Gu Yeo, Sang Won Lee
  • Real-time PCR point mutation assays for detecting HIV-1 resistance to antiviral drugs
    Patent number: 9879317
    Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase, protease, or integrase of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS: 1-89, 96-122, and 124-141. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS: 1-89, 96-122, and 124-141. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV simultaneously or sequentially. Mutations in the reverse transcriptase, protease, or integrase of HIV can be detected using the methods described herein.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: January 30, 2018
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION
    Inventors: Jeffrey A. Johnson, Walid M. Heneine, Jonathan T. Lipscomb
  • Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
    Patent number: 9650422
    Abstract: Disclosed herein is a method for identifying flavivirus cross-reactive epitopes. Also provided are flavivirus E-glycoprotein cross-reactive epitopes and flavivirus E-glycoprotein cross-reactive epitopes having reduced or ablated cross-reactivity (and polypeptides comprising such epitopes), as well as methods of using these molecules to elicit an immune response against a flavivirus and to detect a flaviviral infection.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: May 16, 2017
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Gwong-Jen J. Chang, Wayne D. Crill
  • Selective detection of neisseria meningitidis
    Patent number: 9487832
    Abstract: A process for detecting Neisseria meningitidis nucleic acid in a sample is provided including producing an amplification product by amplifying Neisseria meningitidis nucleotide sequence of the sodC gene or mRNA using a forward primer of SEQ ID NO: 1, and a reverse primer of SEQ ID NO: 2, and detecting the amplification product to detect Neisseria meningitidis in the sample. Also provided are reagents and methods for detecting and distinguishing Neisseria meningitidis from other infectious agents. A kit is provided for detecting and quantifying Neisseria meningitidis in a sample.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: November 8, 2016
    Assignee: The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventor: Jennifer Thomas
  • Recombinant rift valley fever (RVF) viruses and methods
    Patent number: 9439935
    Abstract: Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: September 13, 2016
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Brian H. Bird, Cesar G. Albarino, Stuart T. Nichol, Thomas G. Ksiazek
  • Primate T-lymphotropic viruses
    Patent number: 9435000
    Abstract: Disclosed are compositions and methods related to the isolation and identification of the primate T-lymphotropic viruses, HTLV-3 and HTLV-4. The diversity of HTLVs was investigated among central Africans reporting contact with NHP blood and body fluids through hunting, butchering, and keeping primate pets. Herein it is shown that this population is infected with a variety of HTLVs, including two retroviruses; HTLV-4 is the first member of a novel phylogenetic lineage that is distinct from all known HTLVs and STLVs; HTLV-3 falls within the genetic diversity of STLV-3, a group that has not previously been seen in humans. The present disclosure also relates to vectors and vaccines for use in humans against infection and disease. The disclosure further relates to a variety of bioassays and kits for the detection and diagnosis of infection with and diseases caused by HTLV-3 and HTLV-4 and related viruses.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: September 6, 2016
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention, Johns Hopkins University
    Inventors: William M. Switzer, Walid Heneine, Thomas M. Folks, Nathan D. Wolfe, Donald S. Burke, Eitel Mpoudi Ngole
  • Materials and methods for respiratory disease control in canines
    Patent number: 9345758
    Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: May 24, 2016
    Assignees: University of Florida Research Foundation, Inc., The United States of America as represented by The Secretary of The Department of Health and Human Services, Centers for Disease Control and Prevention, Cornell Research Foundation, Inc.
    Inventors: Patti C. Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, William L. Castleman, Nancy J. Cox
  • Anthrax carbohydrates, synthesis and uses thereof
    Patent number: 9310366
    Abstract: The present invention presents the isolation, characterization and synthesis of oligosaccharides of Bacillus anthracis. Also presented are antibodies that bind to such saccharide moieties and various methods of use for such saccharide moieties and antibodies.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: April 12, 2016
    Assignees: University of Georgia Research Foundation, Inc., The United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Russell W. Carlson, Geert-Jan Boons, Therese Buskas, Elmar Kannenberg, Alok Mehta, Elke Saile, Conrad Quinn, Patricia Wilkins, Mahalakshmi Vasan, Margreet A. Wolfert
  • Photoinduced electron transfer (PET) primer for nucleic acid amplification
    Patent number: 9260746
    Abstract: This application provides photoinduced electron transfer (PET) nucleic acid molecules that can be used detect and amplify nucleic acid molecules, such as target nucleic acid molecules. These PET tags can be attached to the 5?-end of a target sequence-specific primer, thereby generating a PET primer. In particular examples, a PET tag includes a 5?-labeled nucleotide that can be quenched by at least two consecutive Gs within the tag sequence, and is unquenched when the PET tag hybridizes with its complementary nucleic acid molecule. Also disclosed are methods of using PET primers in nucleic acid amplification, such as real-time PCR.
    Type: Grant
    Filed: November 21, 2008
    Date of Patent: February 16, 2016
    Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Jothikumar Narayanan, Vincent Hill
  • Real time PCR assay for detection of bacterial respiratory pathogens
    Patent number: 9260762
    Abstract: Methods for detecting Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella spp. are disclosed. A sample suspected of containing a nucleic acid of one or more of M. pneumoniae, C. pneumoniae, and Legionella spp. is screened for the presence or absence of that nucleic acid. Determining whether the M. pneumoniae, C. pneumoniae, or Legionella spp. nucleic acid is present in the sample can be accomplished by detecting hybridization between a M. pneumoniae probe (such as a CARDS toxin probe), a C. pneumoniae probe (such as a ArgR probe), or a Legionella spp. probe (such as a SsrA probe) and a nucleic acid in a sample. Also disclosed are probes and primers for the detection of M. pneumoniae, C. pneumoniae, and Legionella spp., and kits that contain the disclosed probes and/or primers.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: February 16, 2016
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Jonas M. Winchell, Agnes Warner, Kathleen Thurman
  • Pan-lyssavirus vaccines against rabies
    Patent number: 9248179
    Abstract: Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another lyssavirus, such as Mokola virus, Lagos bat virus and/or West Caucasian bat virus. In particular embodiments, the recombinant rabies virus includes two or three heterologous lyssavirus glycoproteins. The disclosed recombinant rabies viruses can be used as pan-lyssavirus vaccines to provide protection against lyssaviruses that cause rabies.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: February 2, 2016
    Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Xianfu Wu, Charles E. Rupprecht, Ivan V. Kuzmin
  • Dengue serotype 1 attenuated strain
    Patent number: 9169298
    Abstract: The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: October 27, 2015
    Assignees: Centers for Disease Control and Prevention
    Inventors: Richard Kinney, Claire Y. H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
  • Rapid salmonella serotyping assay
    Patent number: 9163287
    Abstract: Processes for the serotype specific detection and identification of one or more Salmonella serotypes are provided. A family of specific primers and probes are provided that allow screening of biological or environmental samples for robust, rapid, and reproducible detection and identification of one or more Salmonella serotypes in the sample.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: October 20, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Patricia Fields, John R. McQuiston, Collette Fitzgerald Leaumont

Find a Lawyer

Justia Legal Resources
© 2020 Justia Legal Portal Company Help Terms of Service Privacy Policy Marketing Solutions